Michael Dougan, MD, PhD
"For me, research is a chance to explore the beauty of the natural world, to learn something new about the human body, and to apply that knowledge to improve health."
Dr. Michael Dougan is currently an Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School and is the Director of the Immunotherapy Mucosal Toxicities Program at Massachusetts General Hospital. He received his MD and PhD from Harvard Medical School, completing his dissertation work in Immunology with Dr. Glenn Dranoff at the Dana-Farber Cancer Institute where he studied the interplay between chronic inflammation, tumor promotion, and antitumor immunity. He completed Internal Medicine Residency and Gastroenterology Fellowship at Massachusetts General Hospital in 2017.
Dr. Dougan’s research focuses on immune regulation in the gastrointestinal tract, using the gastrointestinal toxicities of checkpoint blockade, and immunotherapy more generally, to understand the role of these regulatory receptors in gut homeostasis, as well as the relationship between immune regulation in the gastrointestinal mucosa and the tumor microenvironment. His work aims to translate findings from a detailed analysis of the immune mechanisms driving immunotherapy toxicities into novel treatment strategies for inflammatory diseases of gut, including gastrointestinal immune-related adverse events.
Dr. Dougan is an MRA-funded investigator
